| Family Practice Center Of Abbeville,p.a. | |
|
217 Dothan Rd Abbeville AL 36310-2836 | |
| (334) 585-6421 | |
| (334) 585-6159 |
| Full Name | Family Practice Center Of Abbeville,p.a. |
|---|---|
| Speciality | Family Medicine |
| Location | 217 Dothan Rd, Abbeville, Alabama |
| Authorized Official Name and Position | Bernice Murry Massey (OFFICE MANAGER) |
| Authorized Official Contact | 3345856421 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Family Practice Center Of Abbeville,p.a. 217 Dothan Rd Abbeville AL 36310-2836 Ph: (334) 585-6421 | Family Practice Center Of Abbeville,p.a. 217 Dothan Rd Abbeville AL 36310-2836 Ph: (334) 585-6421 |
| NPI Number | 1891846044 |
|---|---|
| Provider Enumeration Date | 01/15/2007 |
| Last Update Date | 08/22/2020 |
| Medicare PECOS PAC ID | 8022031400 |
|---|---|
| Medicare Enrollment ID | O20060111001054 |
News Archive
Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment of breast cancer. The New Drug Application (J-NDA) for ABRAXANE was filed with the Ministry of Health, Labor and Welfare in 2008.
New Mayo Clinic research has found that survival rates of patients with Barrett's esophagus, (http://www.mayoclinic.org/barretts-esophagus/) which can be a precursor for esophageal cancer, are no different than the survival rates for the general population. These findings were presented today at the 2009 American College of Gastroenterology (http://www.acg.gi.org/) (ACG) Annual Meeting in San Diego.
Gone are the days when people use smart speakers - like Amazon Echo or Google Home -; only as kitchen timers or dinner party music players. These devices have started helping people track their own health, and can even monitor for cardiac arrest.
Aeterna Zentaris Inc. today announced that its Vice President, Alliance Management and Intellectual Property, Eckhard Guenther, Ph.D., will make a presentation on two of the Company's novel anticancer compounds, AEZS-108 and AEZS-129, at Bio Partnering North America on Monday, February 28, 2011, at 4 p.m. in the West Meeting Room 218, of the Vancouver Convention Center in Vancouver, Canada.
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891846044 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | DO-90 (Alabama) | Primary |
| 207Q00000X | Family Medicine | DO-89 (Alabama) | Secondary |
| Provider Name | Richard V Meadows |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1902888407 PECOS PAC ID: 2264435338 Enrollment ID: I20100617000108 |
News Archive
Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment of breast cancer. The New Drug Application (J-NDA) for ABRAXANE was filed with the Ministry of Health, Labor and Welfare in 2008.
New Mayo Clinic research has found that survival rates of patients with Barrett's esophagus, (http://www.mayoclinic.org/barretts-esophagus/) which can be a precursor for esophageal cancer, are no different than the survival rates for the general population. These findings were presented today at the 2009 American College of Gastroenterology (http://www.acg.gi.org/) (ACG) Annual Meeting in San Diego.
Gone are the days when people use smart speakers - like Amazon Echo or Google Home -; only as kitchen timers or dinner party music players. These devices have started helping people track their own health, and can even monitor for cardiac arrest.
Aeterna Zentaris Inc. today announced that its Vice President, Alliance Management and Intellectual Property, Eckhard Guenther, Ph.D., will make a presentation on two of the Company's novel anticancer compounds, AEZS-108 and AEZS-129, at Bio Partnering North America on Monday, February 28, 2011, at 4 p.m. in the West Meeting Room 218, of the Vancouver Convention Center in Vancouver, Canada.
› Verified 5 days ago
| Provider Name | Meredith Roland Mcneal |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1255701256 PECOS PAC ID: 7113227521 Enrollment ID: I20151207002317 |
News Archive
Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment of breast cancer. The New Drug Application (J-NDA) for ABRAXANE was filed with the Ministry of Health, Labor and Welfare in 2008.
New Mayo Clinic research has found that survival rates of patients with Barrett's esophagus, (http://www.mayoclinic.org/barretts-esophagus/) which can be a precursor for esophageal cancer, are no different than the survival rates for the general population. These findings were presented today at the 2009 American College of Gastroenterology (http://www.acg.gi.org/) (ACG) Annual Meeting in San Diego.
Gone are the days when people use smart speakers - like Amazon Echo or Google Home -; only as kitchen timers or dinner party music players. These devices have started helping people track their own health, and can even monitor for cardiac arrest.
Aeterna Zentaris Inc. today announced that its Vice President, Alliance Management and Intellectual Property, Eckhard Guenther, Ph.D., will make a presentation on two of the Company's novel anticancer compounds, AEZS-108 and AEZS-129, at Bio Partnering North America on Monday, February 28, 2011, at 4 p.m. in the West Meeting Room 218, of the Vancouver Convention Center in Vancouver, Canada.
› Verified 5 days ago
News Archive
Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment of breast cancer. The New Drug Application (J-NDA) for ABRAXANE was filed with the Ministry of Health, Labor and Welfare in 2008.
New Mayo Clinic research has found that survival rates of patients with Barrett's esophagus, (http://www.mayoclinic.org/barretts-esophagus/) which can be a precursor for esophageal cancer, are no different than the survival rates for the general population. These findings were presented today at the 2009 American College of Gastroenterology (http://www.acg.gi.org/) (ACG) Annual Meeting in San Diego.
Gone are the days when people use smart speakers - like Amazon Echo or Google Home -; only as kitchen timers or dinner party music players. These devices have started helping people track their own health, and can even monitor for cardiac arrest.
Aeterna Zentaris Inc. today announced that its Vice President, Alliance Management and Intellectual Property, Eckhard Guenther, Ph.D., will make a presentation on two of the Company's novel anticancer compounds, AEZS-108 and AEZS-129, at Bio Partnering North America on Monday, February 28, 2011, at 4 p.m. in the West Meeting Room 218, of the Vancouver Convention Center in Vancouver, Canada.
› Verified 5 days ago
Family Practice Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 217 Dothan Rd, Abbeville, AL 36310 Phone: 334-585-6421 | |
Abbeville Family Health Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 615 Ozark Rd, Abbeville, AL 36310 Phone: 334-585-1171 Fax: 334-585-1182 |